Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (mCRPC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01338012 |
Recruitment Status :
Terminated
(Administrative reasons.)
First Posted : April 19, 2011
Results First Posted : June 5, 2017
Last Update Posted : June 5, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Biological: sipuleucel-T | Phase 2 |
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. The study was divided into Active and Long Term Follow-up (LTFU) Phases.
During the Active Phase eligible subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions. Subjects returned to the clinic for Week 6, Week 10, Month 6, and Month 12 visits. After the Month 12 visit, subjects were to enter the Long Term Follow-up Phase, in which they were contacted every 6 months via telephone.
Study Objectives:
Primary: Evaluate the immune response generated by sipuleucel-T.
Secondary: Evaluate the safety of sipuleucel-T and explore the correlation between sipuleucel-T immune response and overall survival.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402) |
Study Start Date : | December 2011 |
Actual Primary Completion Date : | April 2015 |
Actual Study Completion Date : | April 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: sipuleucel-T
Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
|
Biological: sipuleucel-T
Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Other Name: PROVENGE, APC8015 |
- Number of Study Participants Enrolled and Treated Prior to Study Termination [ Time Frame: Study duration: date of first subject registration Dec 2011 and date of last subject visit April 2015 ]Number of study participants that were enrolled and treated in this trial following completion of study P-11 and prior to study termination.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Previously randomized in Dendreon's P-11 study (NCT00779402) and received at least one infusion of sipuleucel-T
- Radiologic evidence of metastasis
- Castrate resistant prostate cancer. Subjects must have current or historical evidence of disease progression concomitant with surgical or medical castration, as demonstrated by PSA progression OR progression of measurable disease OR progression of non-measurable disease
- Castrate level of testosterone (< 50 ng/dL) achieved via medical or surgical castration
- Adequate hematologic function
Exclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status > 2
- Treatment with chemotherapy within 3 months prior to registration
- Treatment with systemic corticosteroids, abiraterone acetate, external beam radiation therapy, or any investigational product for prostate cancer within 28 days prior to registration
- Treatment with commercial sipuleucel-T (Provenge®)
- Current or imminent pathologic long-bone fracture or spinal cord compression
- Known malignancies other than prostate cancer likely to require treatment within 6 months following registration
- A requirement for systemic immunosuppressive therapy for any reason
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to sipuleucel-T or GM-CSF
- Any infection requiring antibiotic therapy or causing fever within 1 week prior to registration
- Any surgery requiring general anesthetic within 28 days prior to registration

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01338012
United States, California | |
Orange County Urology Associates | |
Laguna Hills, California, United States, 92653 | |
United States, Oregon | |
Oregon Health & Science University | |
Portland, Oregon, United States, 97239 | |
United States, Washington | |
Virginia Mason Hospital | |
Seattle, Washington, United States, 98101 | |
Virginia Mason Medical Center | |
Seattle, Washington, United States, 98101 |
Study Director: | Robert Israel, MD | Valeant Pharmaceuticals North America LLC |
Responsible Party: | Dendreon |
ClinicalTrials.gov Identifier: | NCT01338012 |
Other Study ID Numbers: |
P10-1 |
First Posted: | April 19, 2011 Key Record Dates |
Results First Posted: | June 5, 2017 |
Last Update Posted: | June 5, 2017 |
Last Verified: | June 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
metastatic castrate resistant prostate cancer prostate cancer prostate immune therapy immunotherapy vaccine dendritic cells antigen-presenting cells antigen presenting cells |
cancer vaccine prostatic adenocarcinoma Sipuleucel-T castration resistant prostate cancer (CRPC) booster retreatment immune memory immune response |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |